-
公开(公告)号:US20060148806A1
公开(公告)日:2006-07-06
申请号:US10562128
申请日:2004-07-22
申请人: Susumu Watanuki , Yuji Koga , Hiroyuki Moritomo , Issei Tsukamoto , Daisuke Kaga , Takao Okuda , Fukushi Hirayama , Yumiko Moritani , Jun Takasaki
发明人: Susumu Watanuki , Yuji Koga , Hiroyuki Moritomo , Issei Tsukamoto , Daisuke Kaga , Takao Okuda , Fukushi Hirayama , Yumiko Moritani , Jun Takasaki
IPC分类号: A61K31/503 , C07D471/02 , C07D487/02 , A61K31/4745
CPC分类号: C07D237/28 , A61K31/4709 , A61K31/4725 , C07D215/56 , C07D405/04 , C07F9/5765 , C07F9/60 , C07F9/650947
摘要: A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor.
-
公开(公告)号:US08012959B2
公开(公告)日:2011-09-06
申请号:US12235189
申请日:2008-09-22
申请人: Shinya Nagashima , Hiroshi Nagata , Masashiro Iwata , Masaki Yokota , Hiroyuki Moritomo , Eiichi Nakai , Sadao Kuromitsu , Keiko Ohga , Makoto Takeuchi
发明人: Shinya Nagashima , Hiroshi Nagata , Masashiro Iwata , Masaki Yokota , Hiroyuki Moritomo , Eiichi Nakai , Sadao Kuromitsu , Keiko Ohga , Makoto Takeuchi
IPC分类号: C07D239/48 , A61K31/506
CPC分类号: C07D403/12 , C07D239/48 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D451/04 , C07D453/02 , C07D471/10 , C07D487/08
摘要: A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided.A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.
摘要翻译: 提供了可用于预防或治疗其中涉及STAT6的呼吸系统疾病的化合物,特别是哮喘,慢性阻塞性肺病等。 具有可以被特定取代基取代的芳基氨基或芳基乙氨基的嘧啶衍生物或其盐在2-位被苄基取代的氨基或4-位上的氨基甲酰基和氨基甲酰基, 可以在5位被提供。
-
公开(公告)号:US20100256113A1
公开(公告)日:2010-10-07
申请号:US12680301
申请日:2008-09-25
申请人: Kenichi Onda , Kenichiro Imamura , Fumie Sato , Hiroyuki Moritomo , Yasuharu Urano , Yuki Sawada , Naoki Ishibashi , Keita Nakanishi , Kazuhiro Yokoyama , Shigetada Furukawa , Kazuhiro Momose
发明人: Kenichi Onda , Kenichiro Imamura , Fumie Sato , Hiroyuki Moritomo , Yasuharu Urano , Yuki Sawada , Naoki Ishibashi , Keita Nakanishi , Kazuhiro Yokoyama , Shigetada Furukawa , Kazuhiro Momose
IPC分类号: A61K31/4709 , C07D215/233 , C07D405/12 , C07D401/12 , C07D413/12 , A61K31/47 , A61K31/506 , A61K31/5377 , A61K31/496 , A61K31/4725 , A61K31/55 , A61K31/553
CPC分类号: C07D401/12 , C07D215/233 , C07D401/06 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D491/107
摘要: As a result of extensive studies on NAD(P)H oxidase inhibitors, the present inventors found that a quinolone derivative having, at the 2-position, an alkyl group substituted with a heteroatom or the like has an excellent NAD(P)H oxidase inhibitory activity, and accomplished the present invention. The compound of the present invention has a reactive oxygen species production inhibitory activity based on the NAD(P)H oxidase inhibitory activity, and therefore can be used as an agent for preventing and/or treating diabetes, impaired glucose tolerance, hyperlipidemia, fatty liver, diabetic complications and the like.
摘要翻译: 作为对NAD(P)H氧化酶抑制剂的广泛研究的结果,本发明人发现,在2位具有被杂原子等取代的烷基的喹诺酮衍生物具有优异的NAD(P)H氧化酶 抑制活性,完成了本发明。 本发明的化合物具有基于NAD(P)H氧化酶抑制活性的活性氧产生抑制活性,因此可用作糖尿病预防和/或治疗药物,糖耐量异常,高脂血症,脂肪肝 ,糖尿病并发症等。
-
公开(公告)号:US07488739B2
公开(公告)日:2009-02-10
申请号:US10562128
申请日:2004-07-22
申请人: Susumu Watanuki , Yuji Koga , Hiroyuki Moritomo , Issei Tsukamoto , Daisuke Kaga , Takao Okuda , Fukushi Hirayama , Yumiko Moritani , Jun Takasaki
发明人: Susumu Watanuki , Yuji Koga , Hiroyuki Moritomo , Issei Tsukamoto , Daisuke Kaga , Takao Okuda , Fukushi Hirayama , Yumiko Moritani , Jun Takasaki
IPC分类号: A61K31/47 , C07D215/233 , C07D237/28 , C07D407/02
CPC分类号: C07D237/28 , A61K31/4709 , A61K31/4725 , C07D215/56 , C07D405/04 , C07F9/5765 , C07F9/60 , C07F9/650947
摘要: A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor.
摘要翻译: 包含喹诺酮衍生物或其药学上可接受的盐作为活性成分的血小板聚集抑制剂和用作血小板聚集抑制剂的新型喹诺酮衍生物或其药学上可接受的盐。
-
公开(公告)号:US20070249587A1
公开(公告)日:2007-10-25
申请号:US11576889
申请日:2005-10-05
申请人: Yasuhiro Yonetoku , Kenji Negoro , Kenichi Onda , Masahiko Hayakawa , Daisuke Sasuga , Takahiro Nigawara , Kazuhiko Iikubo , Hiroyuki Moritomo , Shigeru Yoshida , Takahide Ohishi
发明人: Yasuhiro Yonetoku , Kenji Negoro , Kenichi Onda , Masahiko Hayakawa , Daisuke Sasuga , Takahiro Nigawara , Kazuhiko Iikubo , Hiroyuki Moritomo , Shigeru Yoshida , Takahide Ohishi
IPC分类号: A61K31/517 , A61K31/519 , A61K31/55 , A61P3/10 , C07D403/02 , C07D471/04 , C07D495/04
CPC分类号: C07D471/04 , C07D495/04 , C07D513/04
摘要: There are provided novel pyrimidine derivatives which has been fused with an aromatic heterocycle selected from thiophene, thiazole and pyridine or pharmaceutically acceptable salts thereof; and a pharmaceutical composition comprising said compound as an active ingredient. These compounds exhibit excellent promoting activity on insulin secretion and activity against hyperglycemia. Hence, the pharmaceutical compositions comprising such compounds as active ingredients, based on these actions, are useful for treating and/or preventing insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes), insulin-resistant diseases, obesity, and the like.
摘要翻译: 提供已经与选自噻吩,噻唑和吡啶的芳族杂环或其药学上可接受的盐融合的新的嘧啶衍生物; 以及包含所述化合物作为活性成分的药物组合物。 这些化合物对胰岛素分泌表现出优异的促进活性和抗高血糖的活性。 因此,基于这些作用,包含这些化合物作为活性成分的药物组合物可用于治疗和/或预防胰岛素依赖性糖尿病(1型糖尿病),非胰岛素依赖性糖尿病(2型糖尿病),胰岛素抵抗 疾病,肥胖等。
-
公开(公告)号:US20110294749A1
公开(公告)日:2011-12-01
申请号:US13171411
申请日:2011-06-28
申请人: Shinya Nagashima , Hiroshi Nagata , Masahiro Iwata , Masaki Yokota , Hiroyuki Moritomo , Eiichi Nakai , Sadao Kuromitsu , Keiko Ohga , Makoto Takeuchi
发明人: Shinya Nagashima , Hiroshi Nagata , Masahiro Iwata , Masaki Yokota , Hiroyuki Moritomo , Eiichi Nakai , Sadao Kuromitsu , Keiko Ohga , Makoto Takeuchi
IPC分类号: A61K31/505 , C07D413/12 , A61K31/5377 , C07D413/14 , C07D417/12 , A61K31/541 , C07H15/26 , A61K31/7064 , C07D403/12 , A61K31/551 , A61K31/553 , A61P11/06 , A61P11/00 , A61K31/506 , C07D239/48
CPC分类号: C07D403/12 , C07D239/48 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07D451/04 , C07D453/02 , C07D471/10 , C07D487/08
摘要: A compound which may be used for the prevention or treatment of respiratory diseases in which STAT 6 is concerned, particularly asthma, chronic obstructive pulmonary disease and the like is provided.A pyrimidine derivative or a salt thereof, which has an arylamino or arylethylamino group which may be substituted with a specified substituent, at the 2-position, amino group substituted with benzyl group or the like, at the 4-position, and carbamoyl group which may be substituted, at the 5-position, is provided.
摘要翻译: 提供了可用于预防或治疗其中涉及STAT6的呼吸系统疾病的化合物,特别是哮喘,慢性阻塞性肺病等。 具有可以被特定取代基取代的芳基氨基或芳基乙氨基的嘧啶衍生物或其盐在2-位被苄基取代的4-氨基甲酰基和氨基甲酰基上, 可以在5位被提供。
-
-
-
-
-